Hypertriglyceridemia Clinical Trial
Official title:
Estimation of Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene Treatment of Cutaneous T Cell Lymphoma - Pilote Study
Bexarotene is a RXR-selective retinoid, licensed for the treatment of cutaneous T cell lymphoma. The most frequent adverse effect is hypertriglyceridemia but its mechanism is not well known. The purpose of this study is to research a carbohydrate metabolism disorder associated in bexarotene-induced hypertriglyceridemia.
Primary cutaneous lymphomas are the second group of extra nodal lymphomas after
gastrointestinal lymphomas. Bexarotene is licensed for the treatment of epidermotropic
cutaneous T cell lymphoma .The most common side effect of bexarotene is hypertriglyceridemia
(82%) associated with hypercholesterolemia (30 to 40%). Central hypothyroidism is also
present in 40-80% of cases. These adverse effects are dose-dependent. The management of
hyperlipidemia induced by bexarotene is difficult. The mechanism of lipid disorder induced by
bexarotene is not well known. Associated carbohydrate metabolism disorder could be present
and play a role in the bexarotene-induced hyperlipidemia.
The main objective is to estimate the frequency of a carbohydrate disorder in patients with
hypertriglyceridemia (TG> 1.5 g / L) induced by bexarotene treatment of cutaneous T cell
lymphoma, previously free of diabetes, thyroid dysfunction and dyslipidemia.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03929198 -
Translation of Pritikin Program to the Community
|
N/A | |
| Completed |
NCT02250105 -
Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia
|
Phase 2 | |
| Completed |
NCT02859129 -
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
|
Phase 1 | |
| Completed |
NCT01437930 -
Intervention With n-3 Polyunsaturated Fatty Acids (PUFA)-Supplemented Products in Moderate Hypertriglyceridemic Patients
|
N/A | |
| Completed |
NCT01455844 -
TRIal For Efficacy of Capre on hyperTriglyceridemiA
|
Phase 2 | |
| Completed |
NCT01010399 -
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
|
Phase 4 | |
| Completed |
NCT00959842 -
Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia
|
Phase 1/Phase 2 | |
| Completed |
NCT00519714 -
A Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT00186537 -
Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.
|
N/A | |
| Completed |
NCT00246402 -
Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV
|
N/A | |
| Completed |
NCT06020950 -
Chia Seeds Consumption in Hypertriglyceridemia
|
N/A | |
| Completed |
NCT02354976 -
A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.
|
Phase 2 | |
| Completed |
NCT04966494 -
Impact of Beans and Oats Snack Bar on Hypertriglyceridemic Women
|
N/A | |
| Completed |
NCT04630366 -
A Phase 1, First Time in Humans Study of NST-1024
|
Phase 1 | |
| Completed |
NCT04650152 -
Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN)
|
||
| Completed |
NCT03693131 -
Efficacy of MND-2119 in Participants With Hypertriglyceridemia
|
Phase 3 | |
| Completed |
NCT04756180 -
An Efficacy and Safety Study of Omega-3-acid Ethyl Ester in Chinese Subjects With Hypertriglyceridemia.
|
Phase 3 | |
| Completed |
NCT02868177 -
Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes
|
Phase 2/Phase 3 | |
| Completed |
NCT01968720 -
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
|
Phase 2 | |
| Completed |
NCT01462877 -
A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic
|
Phase 4 |